Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001294656 | SCV001483542 | uncertain significance | Idiopathic generalized epilepsy | 2022-12-13 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with RBFOX1-related conditions. This variant is present in population databases (rs769785213, gnomAD 0.003%). This sequence change replaces serine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 93 of the RBFOX1 protein (p.Ser93Ala). ClinVar contains an entry for this variant (Variation ID: 998756). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RBFOX1 protein function. |
Ambry Genetics | RCV003284141 | SCV003984385 | uncertain significance | Inborn genetic diseases | 2023-05-17 | criteria provided, single submitter | clinical testing | The c.277T>G (p.S93A) alteration is located in exon 2 (coding exon 2) of the RBFOX1 gene. This alteration results from a T to G substitution at nucleotide position 277, causing the serine (S) at amino acid position 93 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |